PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 AS MARKER REFLECTING THE DEGREE OF LIPID METABOLISM IMBALANCE AND IT’S ROLE IN CORONARY VASCULAR DISEASE PROGRESSION
Abstract
The aim of the study is to present the scientific literature analysis based relevance of determining levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a marker of hyperlipidemia and to describe its structure and role in cardiovascular diseases pathogenesis. Material and methods. The literature sources published for the past 10 years are observed. The CyberLeninka, PubMed, PMC, PLOS ONE, eLIBRARY.RU are used. The used
keywords are proprotein convertase subtilisin/kexin type 9, hypercholesterolemia. Results. Proprotein convertase subtilisin/kexin type 9 is a new marker reflecting the degree of lipid metabolism imbalance. The PCSK9 structure, its participation in lipid metabolism, factors affecting PCSK9 level and its role in coronary vascular disease progression are described
keywords are proprotein convertase subtilisin/kexin type 9, hypercholesterolemia. Results. Proprotein convertase subtilisin/kexin type 9 is a new marker reflecting the degree of lipid metabolism imbalance. The PCSK9 structure, its participation in lipid metabolism, factors affecting PCSK9 level and its role in coronary vascular disease progression are described
About the Author
Yu. A. Drenina
Surgut District Cardiologic Dispensary
Russian Federation
Cardiologist
Russian Federation
Cardiologist
References
1. Попова А. Б., Нозадзе Д. Н., Сергиенко И. В. Роль PCSK9 в генезе развития сердечно-сосудистых заболеваний // Атеросклероз и дислипидемии. 2016. № 3. С. 5–14.
2. Abifadel M., Varret M., Rabes J. P., Allard D., Ouguerram K., Devillers M. et al. Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia // Nature Genetics. 2003. Vol. 34, No. 2. P. 154–156.
3. Bottomley M. J., Cirillo A., Orsatti L., Ruggeri L., Fisher T. S., et al. Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants // J Biol Chem. 2009. Vol. 284, No. 2. P. 1313–1323.
4. Benn M., Nordestgaard B. G., Grande P., Schnohr P., Tybjaerg-Hansen A. PCSK9 R46L, low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease: 3 Independent Studies and Meta-Analyses // J Am Coll Cardiol. 2010. Vol. 55. P. 2833–2842.
5. Chen Y., Wang H., Yu L., Yu X., Qian Y. W., Cao G., Wang J. Role of Ubiquitination in PCSK9-Mediated Low-Density Lipoprotein Receptor Degradation // Biochemical and Biophysical Research Communications. 2011. Vol. 415, No. 3. P. 515–518.
6. Baass A., Dubuc G., Tremblay M., Delvin E. E., O’Loughlin J., Levy E., Davignon J., Lambert M. Plasma PCSK9 is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents // Clin Chem. 2009. Vol. 55. P. 1637–1645.
7. Han B., Eacho P. I., Knierman M. D., Troutt J. S., Konrad R. J., Yu X., Schroeder K. M. Isolation and Characterization of the Circulating Truncated Fоrm of PCSK9 // A Journal of Lipid Research. 2014. Vol. 55. P. 1505–1514.
8. Lakoski S. G., Lagace T. A., Cohen J. C., Horton J. D., Hobbs H. H. Genetic and Metabolic Determinants of Plasma PCSK9 levels // J Clin Endocrinol Metab. 2009. Vol. 94. P. 2537–2543.
9. Persson L., Cao G., Stahle L., Sjoberg B. G., Troutt J. S., Konrad R. J., Gälman C., Wallén H. et al. Circulating Proprotein Convertase Subtilisin Kexin Type 9 has a Diurnal Rhythm Synchronous with Cholesterol Synthesis and is Reduced by Fasting in Humans // Arterioscler Thromb Vasc Biol. 2010. Vol. 30, No. 12. P. 2666–2672.
10. Awan Z., Seidah N. G., Mac Fadyen J. G., Benjannet S., Chasman D. I., Ridker P. M., Genest J. Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER trial // Clin Chem. 2012. Vol. 58, No. 1. P. 183–189.
11. Davignon J., Dubuc G. Statins and Ezetimibe Modulate Plasma Proprotein Convertase Subtilisin Kexin-9 (PCSK9) Levels // Trans Am Clin Climatol Assoc. 2009. Vol. 120. P. 163–173.
12. Berthold H. K., Seidah N. G., Benjannet S., Gouni-Berthold I. Evidence from a Randomized trial that Simvastatin, but not Ezetimibe, Upregulates Circulating PCSK9 Levels // PLoS One. 2013. Vol. 8, No. 3. P. 1–9.
13. Troutt J. S., Alborn W. E., Cao G., Konrad R. J. Fenofibrate Treatment Increases Human Serum Proprotein Convertase Subtilisin Kexin Type 9 Levels
14. // Journal of Lipid Research. 2010. Vol. 51. P. 345–351.
15. Рос. стат. ежегодник. 2018 : стат. сб. М. : Росстат. 2018. 694 с.
16. Centers for Disease Control and Prevention. Mortality in United States, 2017. NCHS Data Brief No. 328, November 2018 [Электронный ресурс]. URL: https://www.cdc.gov/nchs/products/databriefs/db328.htm (дата обращения: 21.02.2019).
17. European Cardiovascular Disease Statistics 2017 [Электронный ресурс]. URL: http://ehnheart.org/ cvd-statistics/cvd-statistics-2017.html (дата обращения: 05.03.2019).
18. Павлова Т. В., Дупляков Д. В., Воронцова С. А., Гусева Г. Н. Перспективы ведения пациентов со стабильным течением атеросклероза // Кардиология: новости, мнения, обучение. 2018. Т. 6, № 2. С. 9–14.
19. Мешков А. Н., Калинина М. В., Ершова А. И., Косенков Е. И., Щербакова Н. В., Рожкова Т. А., Масенко В. П., Кухарчук В. В., Бойцов С. А. Уровень PCSK9 в семьях пациентов с семейной гиперхолестеринемией // Атеросклероз и дислипидемия. 2012. № 1. C. 12–15.
20. Всероссийское общество орфанных заболеваний. Семейная гиперхолестеринемия [Электронный ресурс]. URL: http://sghs.rare-diseases.ru (дата обращения: 17.03.2019).
21. Джейранова М. О. Семейная гиперхолестеринемия: причины, особенности наследования и прогнозирования // Бюл. мед. интернет-конф. 2018. Т. 8, № 1. C. 8–9.
22. Ежов М. В., Сергиенко И. В., Рожкова Т. А., Кухарчук В. В., Коновалов Г. А., Мешков А. Н., Ершова А. И., Гуревич В. С., Константинов В. О., Соколов А. А., Щербакова М. Ю., Леонтьева И. В., Бажан С. С., Воевода
23. М. И., Шапошник И. И. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии // Атеросклероз и дислипидемии. 2016. Т. 4. С. 21–29.
24. Raal F., Panz V., Immelman A., Pilcher G. Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High-Dose Statin Therapy // Journal of the American Heart Association. 2013. Vol. 2. P. 1–7.
25. Рагино Ю. И., Астракова К. С., Шахтшнейдер Е. В., Стахнеева Е. М., Воевода М. И. Уровни в крови пропротеиновой конвертазы субтилизин-кексинового типа 9 (PCSK9) при гипер- и гипохолестеринемии // Атеросклероз и дислипидемии. 2015. № 4. С. 15–19.
26. Bae K.-H., Kim S. W., Choi Y.-K., Seo J. B. et al. Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute
27. Coronary Syndrome // Diabetes Metab J. 2018. Vol. 42. P. 207–214.
28. Thygesen K., Alpert J. S., Jae A. S., Simoons M. L., Chaitman B. R., White H. D. Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus H.A., Lindahl B. et al. Third Universal Definition of Myocardial Infarction // Circulation. 2012. Vol. 126. P. 2020–2035.
29. Seidah N. G., Awan Z., Chretien M., Mbikay M. PCSK9: a Key Modulator of Cardiovascular Health // Circ Res. 2014. Vol. 114. P. 1022–1036.
30. Zdravkovic V., Mladenovic V., Colic M., Bankovic D., Lazic Z., Petrovic M., Simic I., Knezevic S., Pantovic S., Djukic A., Zdravkovic N. NT-proBNP for Prognostic and Diagnostic Evaluation in Patients with Acute Coronary Syndromes // Kardiol Pol. 2013. Vol. 71. P. 472–479.
Review
For citations:
Drenina Yu.A. PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 AS MARKER REFLECTING THE DEGREE OF LIPID METABOLISM IMBALANCE AND IT’S ROLE IN CORONARY VASCULAR DISEASE PROGRESSION. Vestnik SurGU. Meditsina. 2019;(2 (40)):100-104. (In Russ.)
Views:
321
Email this article 
